Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

Proliferation Marker Inhibitors

Proliferation Marker Inhibitors, also known as cell proliferation inhibitors, represent a distinct class of chemical compounds designed to interfere with the fundamental biological process of cell proliferation. Cell proliferation is a crucial mechanism in multicellular organisms, facilitating tissue growth, repair, and regeneration. In pathological conditions, however, uncontrolled cell proliferation can lead to the development of diseases like cancer. Proliferation Marker Inhibitors are primarily designed to target and regulate the activity of specific biomarkers or signaling pathways associated with cell division. By doing so, they aim to arrest or slow down the rate at which cells multiply, effectively impeding the progression of proliferative diseases.

These inhibitors often work by targeting key molecules involved in cell cycle regulation, DNA replication, or signal transduction pathways. They can interfere with various stages of the cell cycle, including G1, S, G2, and M phases, depending on their specific mechanism of action. Proliferation Marker Inhibitors may also exhibit selectivity towards cancer cells, exploiting the differences in proliferation markers between normal and malignant cells. By disrupting these markers or pathways, these inhibitors can halt the uncontrolled division of cancer cells, making them a potential tool in cancer research. Additionally, they hold promise in various other fields of biology and research, where precise control over cell proliferation is necessary to understand and manipulate biological processes.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Gefitinib is a tyrosine kinase inhibitor targeting EGFR (Epidermal Growth Factor Receptor), blocking downstream signaling pathways that promote cell proliferation.

Imatinib mesylate

220127-57-1sc-202180
sc-202180A
25 mg
100 mg
$44.00
$109.00
61
(1)

Imatinib inhibits BCR-ABL kinase, disrupting the signaling cascade responsible for uncontrolled cell proliferation in chronic myeloid leukemia (CML).

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

Palbociclib inhibits CDK4/6, preventing phosphorylation of retinoblastoma protein (Rb) and halting cell cycle progression in estrogen receptor-positive breast cancer cells.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib targets multiple kinases in the RAF/MEK/ERK pathway, as well as VEGFR and PDGFR, inhibiting angiogenesis and proliferation in various cancer types.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

Everolimus inhibits mTOR (mammalian target of rapamycin), reducing protein synthesis and cell growth in tumors, particularly in renal cell carcinoma.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib is a MEK inhibitor that blocks the downstream ERK signaling pathway, impairing cell proliferation in BRAF-mutated melanomas.

Abemaciclib

1231929-97-7sc-507342
10 mg
$110.00
(0)

Abemaciclib selectively inhibits CDK4 and CDK6, leading to Rb protein hypophosphorylation and cell cycle arrest in estrogen receptor-positive breast cancer.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

Ruxolitinib inhibits JAK1 and JAK2, disrupting the JAK-STAT signaling pathway, reducing cell proliferation in myelofibrosis and polycythemia vera.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Ibrutinib inhibits BTK (Bruton's tyrosine kinase), suppressing B-cell signaling and proliferation, studied in the research of B-cell malignancies like CLL and MCL.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Dasatinib targets multiple tyrosine kinases, including BCR-ABL and Src family kinases, disrupting signaling pathways that promote cell proliferation in leukemia.